Daprodustat for Anemia in Chronic Kidney Disease
Author Information
Author(s): Waheed Yousuf Abdulkarim, Liu Jie, Almayahe Shifaa, Sun Dong
Primary Institution: Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
Hypothesis
Can daprodustat effectively treat anemia in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients?
Conclusion
Daprodustat has shown efficacy in increasing hemoglobin levels and improving anemia in chronic kidney disease patients.
Supporting Evidence
- Daprodustat has been shown to increase hemoglobin levels in both dialysis and non-dialysis CKD patients.
- Clinical studies indicate that daprodustat is well tolerated and effective in managing anemia.
- Daprodustat treatment resulted in a significant decrease in hepcidin levels, improving iron metabolism.
Takeaway
Daprodustat is a new medicine that helps people with kidney problems make more red blood cells, which can help them feel better.
Methodology
This review summarizes various clinical trials and studies on daprodustat's effects on anemia in CKD patients.
Potential Biases
Potential biases in trial designs and reporting of adverse effects.
Limitations
Long-term safety and efficacy of daprodustat need further investigation.
Participant Demographics
Patients with chronic kidney disease, both on dialysis and not on dialysis.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI: 0.03 to 0.13
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website